Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Bad
|
New words:
activin, acumen, ADC, ADT, alleviate, androgen, antigen, Avenue, banc, Belgium, Biogen, bomedemstat, Cantonal, carcinogenic, carcinogenicity, Cardiology, caregiving, Carolina, ceiling, CEO, Chirfi, circular, Clalit, College, Colombia, Colorado, Columbia, Connecticut, Conrad, contested, counting, creation, curiam, cytochrome, deadline, demethylase, deployment, derazantinib, diligently, disagree, domain, donating, donation, elderly, en, endocrine, Energize, engineered, facie, faster, fc, FCPA, Finnish, flextime, fluidly, fuel, Glenmark, Greece, Guindo, hardship, HRSA, humanitarian, hyaluronidase, hybrid, IB, IIIA, Imago, incidence, intervene, invaded, invited, involuntary, Israel, JiXing, job, Joseph, kind, Lagevrio, Lincoln, longest, lymphatic, Macau, macro, mainland, marrow, Mectizan, menu, metformin, metric, mice, MMWR, multicomponent, multilateral, myeloproliferative, Natco, natriuretic, neglected, NEJM, newer, nitrosamine, node, North, NTTP, Orion, orna, orthostatic, outmoded, overcharging, overhead, Oxford, PANORAMIC, Pedcev, peptide, phosphodiesterase, pioneering, Playbook, PMBLC, polycythemia, preclinical, prednisolone, prednisone, prima, purported, radiographic, Ratio, reassessment, reconciling, rehearing, relief, RNA, robust, Romanelli, running, SBTi, schizophrenia, Schneider, session, shape, shorter, Sichuan, signatory, sorafenib, STELLAR, steroid, stored, successor, summer, switch, symptom, tachycardia, Taiwan, telework, thrive, thrombocythemia, tool, trace, transgenic, trebling, trophoblast, tropical, uncovering, undergone, underserved, unlawful, unlocking, unnamed, untreated, upheld, upholding, vera, walk, waning, winning, wrote, younger
Removed:
affirmed, Albrecht, ALK, allocating, Antelliq, appellate, aprepitant, arbitrability, attack, bilateral, borrowed, Brexit, causation, clarify, compel, concluding, County, CPS, curable, detailed, divestiture, EGFR, Emend, employing, enhance, estimating, executing, expression, femur, fight, finalized, Fosamax, fracture, Frazier, freedom, Galloping, genomic, genotype, Gerberding, granting, GT, guard, Hill, hormonal, immunotherapy, improving, incorrectly, India, inoperable, institute, intraperiod, IOmet, Julie, jury, Kenneth, label, lapse, leader, left, Los, match, MCC, Mexico, modernize, movement, nausea, notice, package, partnered, Peloton, platinum, plexiform, predominantly, preempted, preemption, PROfound, proposed, question, reconsider, referenced, referendum, remanding, reorganization, repay, reprioritization, requirement, resiliency, reversing, Road, simplify, skin, somatic, Southern, speed, spent, SPRINT, Station, Stratum, Supreme, susceptible, toll, Turkey, VICTORIA, vivo, vomiting, Whitehouse, Zepatier
Filing tables
Filing exhibits
- 10-K Annual report
- 10.7 EXHIBIT-10.7 2017 Annual Nqso Terms and Conditions
- 10.8 EXHIBIT-10.8 2019 Annual Nqso Terms and Conditions
- 10.13 EXHIBIT-10.13 Us Separation Benefits Plan As of 1/1/19
- 10.23 EXHIBIT-10.23 2019 Annual CEO Nqso Terms and Conditions
- 10.24 EXHIBIT-10.24 2019 Annual Rsu Terms and Conditions
- 10.25 EXHIBIT-10.25 2020 Annual Nqso Terms and Conditions
- 10.26 EXHIBIT-10.26 2020 Annual CEO Nqso Terms and Conditions
- 10.27 EXHIBIT-10.27 2020 Annual Rsu Terms and Conditions
- 10.28 EXHIBIT-10.28 2020 Annual Psu Terms and Conditions
- 10.29 EXHIBIT-10.29 2020 Annual CEO Psu Terms and Conditions
- 10.30 EXHIBIT-10.30 2021 Annual CEO Nqso Terms and Conditions
- 10.31 EXHIBIT-10.31 2021 Annual Psu Terms and Conditions
- 10.32 EXHIBIT-10.32 2021 Annual CEO Psu Terms and Conditions
- 10.33 EXHIBIT-10.33 2021 Special Retention Rsu Terms and Conditions
- 10.34 EXHIBIT-10.34 2022 Executive Chairman Rsu Terms and Conditions
- 10.35 EXHIBIT-10.35 2022 Annual Rsu Terms and Conditions (Guindo)
- 10.36 EXHIBIT-10.36 2022 Annual Psu Terms and Conditions (Guindo)
- 10.37 EXHIBIT-10.37 Offer Letter (Guindo)
- 21 EXHIBIT-21 Subsidiary List
- 23 EXHIBIT-23 Consent of Independent Registered Public Accounting Firm
- 24.1 EXHIBIT-24.1 Power of Attorney
- 24.2 EXHIBIT-24.2 Certification of Board Resolution
- 31.1 EXHIBIT-31.1 Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 EXHIBIT-31.2 Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 EXHIBIT-32.1 Section 1350 Certification of CEO
- 32.2 EXHIBIT-32.2 Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
Associated MRK transcripts
MRK similar filings
Filing view
External links
Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-254700 and 333-254703) and on Form S-8 (Nos. 333-173025, 333-173024, 333-162883, 333-162884, 333-162885, 333-162886, 333-121089, and 333-233226) of Merck & Co., Inc. of our report dated February 24, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 24, 2023